Efficacy and safety of Yinaokang capsules on functional recovery after acute ischemic stroke: protocol for a pilot, prospective, randomized, open-label, blinded-endpoint trial
Abstract
Background: Previous studies suggest that Yinaokang Capsules (YNKC) may offer therapeutic benefits for acute ischemic stroke (AIS) by reducing atherosclerosis, inhibiting inflammatory mediators, and exhibiting neuroprotective properties. Nonetheless, there is currently a lack of substantial clinical data that validates the overall efficacy and safety of YNKC. Furthermore, the systemic metabolic changes that underpin its neurovascular protective effects have not been thoroughly investigated in clinical contexts.
Methods: This study is a prospective, randomized, open-label, blinded-endpoint trial designed to enroll 80 patients diagnosed with AIS aged between 18 and 80 years at the Guangdong Provincial Hospital of Chinese Medicine. Eligible participants must present within 72 h of symptom onset and have a baseline National Institutes of Health Stroke Scale (NIHSS) score ranging from 4 to 22. Participants will be randomly assigned in a 1:1 ratio to either the YNKC group or the control group. Those in the YNKC group will receive four YNKC orally three times daily for a duration of 14 days. All participants will concurrently receive standard guideline-based medical treatment. The primary efficacy outcome will be the proportion of patients achieving a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0 to 1 at day 90 following randomization. Secondary outcomes included the overall distribution of mRS scores, NIHSS score, Montreal Cognitive Assessment…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 80 participants or records.
Read the paper
Related studies
- Quercetin Influences Quorum Sensing in Food Borne Bacteria: In-Vitro and In-Silico Evidence
- Phenolic-protein interactions: insight from in-silico analyses – a review
- In Silico Discovery of Candidate Drugs against Covid-19
- Neuropharmacological Effects of Quercetin: A Literature-Based Review
- In vitro and in silico anti-dengue activity of compounds obtained from Psidium guajava through bioprospecting
- Effect of Quercetin Rich Onion Extracts on Bacterial Quorum Sensing
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.